Go Pro
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel
NASDAQ:IMNM

Immunome Q2 2026 Earnings Report

Immunome logo
$25.72 +0.69 (+2.76%)
As of 03:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Immunome EPS Results

Actual EPS
N/A
Consensus EPS
-$0.51
Beat/Miss
N/A
One Year Ago EPS
N/A

Immunome Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.17 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immunome Announcement Details

Quarter
Q2 2026
Date
8/12/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Immunome Earnings Headlines

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
July 20, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260720175949/en/Immunome-Announces-First-Patient-Dosed-in-Phase-1-Trial-Evaluating-IM-3050-an-FAP-Targeted-Radioligand-Therapy-in-Patients-with-FAP-Expressing-Advanced-Solid-Tumors/
What This Immunome Sale Means a Day Before a Big FDA Milestone
July 12, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/07/12/what-this-immunome-sale-means-a-day-before-a-big-fda-milestone/
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
August 10 at 1:00 AM  |  Stansberry Research (Ad)
Immunome granted FDA review for tumor candidate
July 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4612281-immunome-granted-fda-review-for-tumor-candidate
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
July 8, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260708283482/en/Immunome-Announces-U.S.-FDA-Acceptance-of-New-Drug-Application-for-Varegacestat-for-the-Treatment-of-Adults-with-Desmoid-Tumors/
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 7, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260707694125/en/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4/
See More Immunome Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your email.

About Immunome

Immunome (NASDAQ:IMNM) is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens. In parallel, Immunome is advancing additional candidates in solid tumors, including antibody–drug conjugates and immunomodulatory antibodies that aim to stimulate anti-tumor immune responses. Beyond oncology, the platform has been applied to infectious disease programs, where candidate antibodies against emerging viral threats have been identified and optimized for potential therapeutic or prophylactic use.

Founded in the early 2000s and headquartered in Ann Arbor, Michigan, Immunome has grown from a privately held research operation into a publicly traded company listed on the Nasdaq exchange under the ticker “IMNM.” In 2021, the company completed its initial public offering, providing capital to support ongoing clinical development and platform expansion. Led by President and Chief Executive Officer Greg Bailey, Immunome maintains collaborations with academic institutions and industry partners to advance its pipeline and explore new therapeutic applications of its discovery platform.

View Immunome Profile
Earnings Tools